Gene therapy, ophthalmology research, and biotechnology innovation by Ocugen
Ocugen, Inc. appoints Mohamed Genead as chief medical officer to lead therapy development
Ocugen, Inc. has announced the appointment of Mohamed Genead, MD, MSc as its new chief medical officer. With more than 20 years of expertise in ophthalmology, gene therapy, and retinal disease ...
OCU400 positioned as potential one-time gene therapy, Ocugen, Inc. moves toward regulatory filing
Ocugen, Inc. is progressing OCU400, a gene therapy designed to address multiple mutations causing retinitis pigmentosa, toward a planned Biologics License Application (BLA) submission this year. ...
Ocugen, Inc. reports 54 percent decline in atrophic lesion growth in OCU410ST early results
Ocugen, Inc. has published early results for its OCU410ST clinical trial, revealing a 54 percent reduction in the growth of atrophic lesions among treated patients. According to the company, 100 ...
Ocugen targets inherited retinal diseases with new gene therapy approach
Ocugen, Inc. has introduced its latest modifier gene therapy platform aimed at treating inherited retinal and blindness diseases, presenting the technology at three major conferences this month. ...
Ocugen, Inc. pursues breakthrough for 100,000 with Stargardt disease as OCU410ST shows early promise
Ocugen, Inc. is targeting a critical medical need for more than 100,000 people affected by Stargardt disease, a rare inherited eye condition with no FDA approved treatment to date. The ...
Gene therapy pipeline accelerates as Ocugen, Inc. targets approvals for RP and Stargardt disease
Ocugen, Inc. is accelerating development of potentially one-time gene therapies targeting inherited retinal diseases such as retinitis pigmentosa (RP), Stargardt disease, and geographic atrophy ...
Ocugen, Inc. advances automation in quantitative autofluorescence for geographic atrophy at ARVO2026
Ocugen, Inc. presented new research at the ARVO2026 conference, introducing automation to reduce variability in quantitative autofluorescence measurements for patients with geographic atrophy and ...
OCGN cash outlook extends to 2028 as OCU400 and OCU410ST enrollment completes
Ocugen, Inc. announced a first quarter 2026 update, revealing that the company anticipates its cash position will support operations into 2028. The update includes positive data from its OCU410 ...
Ocugen, Inc. advances gene therapy platform as CEO and EVP present at global biotech events
Ocugen, Inc. announced that CEO Dr. Shankar Musunuri and Abhi Gupta, Executive Vice President of Commercial and Business Development, will present at international biotech conferences on April 28. ...
Ocugen, Inc. outlines mass-market gene therapy push with planned BLAs for blindness treatments
Ocugen, Inc. aims to bring gene therapy to a wider patient base with plans to pursue three Biologics License Applications (BLAs) by 2028 for one-time treatments targeting blindness diseases. CEO ...
Ocugen, Inc. reports 31 percent drop in GA lesion growth with OCU410 medium dose in phase 2 trial
Ocugen, Inc. announced that its investigational therapy OCU410, when administered at a medium dose, led to a 31 percent reduction in geographic atrophy (GA) lesion growth in phase 2 clinical ...
OCU410 shows nearly double treatment effect over approved therapies, Ocugen, Inc. asserts
Ocugen, Inc. has unveiled topline results from its Phase 2 ArMaDa trial for OCU410, showing a 31 percent reduction in geographic atrophy (GA) lesion growth at 12 months compared to control. The ...
Ocugen, Inc. targets 100s of mutations with gene therapies to address 132 billion dollar vision loss burden
Ocugen, Inc. is advancing one-time gene therapies designed to address hundreds of genetic mutations responsible for vision loss, with ambitions to tackle the 132 billion dollar annual global ...
Retinal specialists drive clinical progress on modifier gene therapy, Ocugen, Inc. asserts
Ocugen, Inc. recognizes retinal surgeons for their contributions to the advancement of modifier gene therapy through participation in clinical trials and advisory roles. The company notes that ...
Ocugen, Inc. unveils 12-month Phase 2 data for OCU410 gene therapy in GA
Ocugen, Inc. announced encouraging 12-month results from its Phase 2 trial of OCU410, a one-time gene therapy targeting geographic atrophy (GA). Initial data indicate a measurable impact on both ...
Ocugen, Inc. pushes innovation in modifier gene therapies to address blindness
Ocugen, Inc. is accelerating the development of innovative modifier gene therapies aimed at tackling major causes of blindness. With millions of people affected by vision loss, the company ...
Ocugen, Inc. honors women leaders advancing gene therapy innovation
Ocugen, Inc. is marking the 115th anniversary of International Women’s Day by honoring the women who shape the company’s mission and innovative approach to gene therapies. The company ...
Employee dedication drives gene therapy progress, Ocugen, Inc. asserts
Ocugen, Inc. has recognized the dedication and collaborative spirit of its employees on Employee Appreciation Day. The company credits its workforce as being instrumental in moving its gene ...
Ocugen, Inc. completes OCU400 Phase 3 and secures first OCU400 licensing deal amid leadership boost
Ocugen, Inc. has closed 2025 with a series of significant milestones, including the completion of Phase 3 trials for its OCU400 therapy for retinitis pigmentosa, positive Phase 2 results for ...
Ocugen, Inc. advances gene therapies for rare inherited retinal diseases amid global support
Ocugen, Inc. has reaffirmed its commitment to developing novel modifier gene therapies targeting rare inherited retinal diseases with significant unmet patient needs. The company publicly ...
Ocugen foresees gene-agnostic therapies advancing blindness treatment
Ocugen, Inc. is exploring the potential of gene-agnostic modifier therapies to become a leading method in treating major blindness diseases. This innovative approach could significantly broaden ...
